Canada and EU may extend MRA (mutual recognition agreement) transition period:
This article was originally published in Clinica
Executive Summary
There may be a delay in the final implementation of the mutual recognition agreement (MRA) between Europe and Canada. The accord, which covers a number of sectors including medical devices, came into force on November 1 last year and a confidence building phase is now underway. This phase was expected to last 18 months. However, "an extension is likely as the implementation is complex", involving both the technical dossier review and quality systems, according to Dorothy Walker, the MRA co-ordinator for the Canadian Medical Devices Bureau.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.